The "Achilles heel" of invasive coronary angiography is its inability to accurately localize which stenoses induce ischemia and warrant treatment. Fractional flow reserve (FFR) is a coronary wire-based physiologic index that measures the functional significance of epicardial stenoses, thereby overcoming this limitation. Over the past decade, the landmark FAME (Fractional Flow Reserve vs Angiography for Multivessel Evaluation) trials demonstrated the clinical utility of an FFR-guided strategy for percutaneous coronary intervention (PCI) compared with angiography-only PCI or medical therapy alone in patients with predominantly stable ischemic heart disease. These trials have spurred the current era of coronary-physiology-guided revascularization.
View details for DOI 10.1016/j.iccl.2020.05.001
View details for PubMedID 32921365